Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 465

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 465
---
 Kadimastem is anticipated to be the accounting acquirer because it is anticipated to control the board of directors, management of the combined company, and the preexisting shareholders of Kadimastem are currently anticipated to have the majority voting rights of the combined company. 2.Pro Forma Adjustments The Company is providing the unaudited pro forma condensed combined information for illustrative purposes only and such pro forma information does not represent the consolidated results or financial position of the Company had its acquisition of Kadimastem been completed as of the dates indicated. The companies may have performed differently had they been combined during the periods presented. Specifically, the unaudited pro forma condensed combined financial information does not reflect any cost savings, operating synergies, revenue enhancements or restructuring costs that the combined company may achieve or incur as a result of the acquisition. You should not rely on the unaudited pro forma condensed combined financial information as being indicative of the historical results that would have been achieved had the companies been combined during the periods presented. Further, the unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the combined company. The pro forma adjustments in the unaudited pro forma condensed combined balance sheet as of December 31, 2024 and statement of operations for the twelve months ended December 31, 2024 are as follows: (A)To record net proceeds of $475,000 in connection sale of 161,290 NLS Common Shares at a purchase price of $3.10 per share on January9, 2025 pursuant to the securities purchase agreement with an accredited investor dated December4, 2024; (B)To record gross proceeds of $178,699 received in January 2025 related to exercise of warrants for a total of 76,847 NLS Common Shares in connection with the securities purchase agreement with certain accredited investors dated October9, 2024 and pre -fundedwarrants provided to certain institutional investors upon execution of warrant amendment agreements; (C)To record gross proceeds of $1,900,000 in connection with issuance of 1,212,122 preferred shares of NLS, CHF 0.03 nominal value per share (“Preferred Shares”), issued in a private placement offering with three accredited investors entered on March27, 2025 with a conversion price of $1.65 per share; (D)Adjustment to remove $104,963 of interest expenses related to loans converted at closing as noted above as if